Drug Trial Radar · NCT05753865
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
Last checked: Nov 19, 2026Latest source record: Mar 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
454
Planned (sponsor's estimate)
Start
May 1, 2023
Primary completion
Sep 1, 2024
Study completion Sep 1, 2024
Sponsor
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety in patients with advanced breast cancer treated with SYHX2011 versus paclitaxel for injection (albumin-bound).
Conditions
- Advanced Breast Cancer
Interventions
SYHX2011Drug
IV infusion, 260 mg/m\^2
Paclitaxel for injection (albumin-bound)Drug
IV infusion, 260 mg/m\^2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by IRCTime frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.